Log In
Print this Print this

Trisenox, arsenic trioxide

Also known as: ATO

  Manage Alerts
Collapse Summary General Information
Company Teva Pharmaceutical Industries Ltd.
DescriptionArsenic trioxide that causes DNA fragmentation and damage to promyelocytic leukemia-retinoic acid receptor alpha (PML-RARA) fusion protein
Molecular Target DNA
Mechanism of ActionUnknown
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationAcute promyelocytic leukemia (APL)
Indication DetailsTreat acute promyelocytic leukemia (APL); Treat acute promyelocytic leukemia (APL) in combination with retinoic acid; Treat refractory acute promyelocytic leukemia (APL); Treat relapsed or refractory acute promyelocytic leukemia (APL)
Regulatory Designation Australia - Orphan Drug (Treat acute promyelocytic leukemia (APL))
PartnerH. Lundbeck A/S;
Nippon Shinyaku Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today